NeOnc reports Phase 2a NEO100 trial hits six-month PFS endpoint in recurrent IDH1-mutant high-grade glioma
NTHI•Next regulatory step
NeOnc plans an FDA Type B meeting to discuss a registrational path.
The full Phase 2a dataset is expected to be presented at a future medical meeting.
Survival and safety findings
Survival outcomes were described as encouraging, with several patients remaining on treatment and signs of durable disease control.
The safety profile appeared favorable, with no major toxicities reported.
Phase 2a trial met primary endpoint
NeOnc reported positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma.
The study met its primary endpoint, supporting a meaningful delay in disease worsening versus standard expectations in this setting.
